Cai Lay Veterinary Pharmaceutical JSC Shows Strong Financial Performance and Attractive Valuation Metrics

Cai Lay Veterinary Pharmaceutical JSC has recently undergone an adjustment in its evaluation, reflecting notable shifts in its financial metrics. The company operates within the Pharmaceuticals & Biotechnology sector and is categorized as a microcap entity. The valuation grade for Cai Lay has transitioned to an attractive status, supported by a P/E ratio of 7 and a Price to Book Value of 1.00. Additionally, the company exhibits a robust EV to EBIT ratio of 2.89 and an EV to EBITDA ratio of 2.42, indicating a favorable valuation landscape. The PEG ratio stands at a low 0.06, further emphasizing its valuation appeal. In terms of performance indicators, Cai Lay has reported a significant net profit of VND 8,033.14 million, showcasing a growth rate of 263.23%. The operating cash flow reached its highest at VND 20,353.84 million, while net sales for the first nine months amounted to VND 117,655.23 million, reflecting a growth of 28.07%. The company's return on equity (ROE) is recorded at 15.22%, reinforcing its strong financial standing. Overall, the recent evaluation adjustment highlights the company's solid financial performance and attractive valuation metrics. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.